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The evidence-based approach to
adult-onset idiopathic nephrotic
syndrome
Pietro A. A. Canetta* and Jai Radhakrishnan
Division of Nephrology, Department of Medicine, Columbia University Medical Center, Columbia University College of Physicians
and Surgeons, New York, NY, USA
Adult-onset nephrotic syndrome (NS) differs from its pediatric counterpart in several
important ways. Most importantly, NS in adults is more etiologically heterogeneous
compared to children, and thus treatment approaches rely heavily on the histological
diagnosis provided by renal biopsy. The evidence-based approach to treatment of adult
NS has been critically examined by the Kidney Disease Improving Global Outcomes
(KDIGO) guidelines in glomerulonephritis, published in 2012. Here, we examine the
strengths and limits of those guidelines and review recent work that expands the
evidence-based approach.
Keywords: nephrotic syndrome, minimal-change disease, focal segmental glomerulosclerosis, KDIGO guidelines,
clinical practice guidelines
Introduction
The field of nephrology carries the dubious distinction of consistently producing the fewest number
of randomized controlled trials among the internal medicine specialties (1, 2). Within nephrology,
glomerular diseases have been particularly neglected, especially the primary glomerular diseases,
including idiopathic nephrotic syndrome (NS) (3, 4). Consequently, high-quality clinical evidence to
guide treatment decisions in NS has been sparse, and nephrologists have long navigated thesemurky
waters according to principles of physiology and insights gleaned fromobservational or uncontrolled
studies.
With these limitations inmind, a Kidney Disease Improving Global Outcomes (KDIGO) working
group attempted to synthesize the available evidence into a series of disease-specific clinical practice
guidelines for glomerulonephritis, published in 2012 (5). These guidelines were pioneering in that
nothing so comprehensive with respect to glomerular diseases had ever been produced by one of the
field’s major organizations. Other systematic reviews have examined specific diseases or problems in
NS [particularly noteworthy areCochrane reviews covering corticosteroid use, immunosuppression,
and lipid-lowering therapy (6–8)], but none claimedbroad consensus to establish practice guidelines.
Clinical practice guidelines serve several important purposes to clinicians and researchers (9). By
critically synthesizing and grading the quality of the evidence base, they help define not only what
is optimal but also the breadth of what is reasonable. By defining the limits of current evidence, they
highlight those areas where evidence is lacking to justify adoption or broad endorsement of specific
practices.
Using the KDIGO guidelines as a foundation, we here examine the evidence-based approach
to adult-onset NS, limiting the discussion to minimal-change disease (MCD) and focal seg-
mental glomerulosclerosis (FSGS). Strikingly, of the recommendations offered in the KDIGO
guidelines, over 75% were considered to be based on low- or very low-quality evidence
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(grade C and D, respectively). In particular, for adult MCD and
adult FSGS, a total of 23 statements were made of which only
2 (8.7%) were level 1 recommendations, both based on grade
C evidence. No statement was supported by grade A evidence,
and only one suggestion was graded B (moderate quality). Of
the remaining 20 statements, 17 were classified as suggestions
based on low- or very low-quality evidence (2C or 2D), and three
statements (13%) lacked evidence to be graded at all. This is a
sobering picture of the limits of evidence that define the “state of
the art” in the clinical management of adult NS.
Comparing Adult-Onset to Pediatric
Nephrotic Syndrome
Adult-onset NS differs from its pediatric counterpart in several
important ways. The prospective International Study of Kidney
Diseases in Children showed that in children aged 1–16 pre-
senting with NS, there was a 95% likelihood of responding to a
course of glucocorticoids by 16weeks (10). This finding justified
the recommendation that kidney biopsy not be routinely done
immediately in nephrotic children, but rather deferred to those
not responding to (or relapsing after) an empiric course of cor-
ticosteroids. Importantly, most children presenting with NS will
have MCD, although the incidence of other diagnoses appears
to be increasing (particularly FSGS) and these account for most
treatment-resistant cases (11, 12). In adults, NS comprises a much
more diverse group of diseases, with considerable demographic
variation, including both primary and secondary conditions (13,
14). For this reason, early kidney biopsy is critical to properly cat-
egorize the disease and direct the subsequent clinical approach in
adults. Among primary or idiopathic diseases, the most common
remain FSGS, membranous nephropathy, and MCD. Because this
Frontiers research topic is primarily concerned with pediatric
NS, we will focus on MCD and FSGS, which also cause the
majority of pediatric NS and where comparisons may be most
fruitful.
The prevalence of genetic causes of NS is unsurprisingly dif-
ferent between pediatric and adult populations. An increasing
number ofmonogenetic defects have been found to cause neonatal
or childhood NS, most of which affect genes critical to podocyte
function, follow autosomal recessive transmission, and histologi-
cally produce FSGS (15, 16). The precise role for genetic screen-
ing remains ill-defined. The KDIGO guidelines did not endorse
screening, stating that
Routine evaluation for genetic mutations is not recom-
mended in this guideline due to the variable availability
of genetic testing, significant cost, low to absent preva-
lence observed in some populations, and the lack of
systematic studies of treatment response and prognosis
relative to specific genetic polymorphisms (5)
Reconsideration of such claims should be prompted by the pace
of discovery and technological improvements in genetic diagnosis,
precipitously falling costs, expanding availability, and progress in
understanding the clinical consequences of mutations.
Genetic variantsmay predict with high accuracy which patients
will have steroid-resistant disease, potentially allowing a clinician
to spare them from toxic empiric therapy (17). Emerging research
suggests that theremay also be a genetic signal for steroid-sensitive
disease (18). Certain mutations also predict freedom from relapse
following transplantation (15). Mutations are increasingly being
found in older patients with NS. A recent publication from the
SRNS Study Group showed that a single-gene cause of steroid-
resistant NS could be identified in nearly a third of affected
families, including>10%where disease onset was between 13 and
18 years of age (19). Santín and colleagues likewise identified a
high proportion of mutations in Spanish patients with primary
NS, including 14% among adults (median age of onset 33 years),
and proposed a screening algorithm based on age of onset and
whether disease was familial or sporadic (20). Such algorithms
will need to be validated and adjusted based on local demograph-
ics, testing availability, and reimbursement practices, but with
the advancements in speed and affordability of next-generation
sequencing there is already reasonable justification for screening
selected patients in the clinic.
Adult Minimal-Change Disease
Adult MCD shares many similarities to the pediatric form,
although time to remission appears prolonged and acute kidney
injury more common, whereas the risk of relapse may be less
(21–23). The largest published series of adult MCD included
340 Chinese patients (24). Only 9.7% were steroid resistant, the
remainder reached remission in a median of 10weeks. During
follow-up, 42% of responders relapsed, and 27% became frequent
relapsers or steroid dependent (FR/SD). Certain groups may have
highermorbidity. In a series of 95 adults seen at our referral center,
almost all treated with steroids, 25% presented with acute kidney
injury (25).Mean time to remissionwas 13weeks, but one-quarter
were steroid-resistant and 73% of responders relapsed, with 41%
of responders frequently relapsing.
The KDIGO guidelines for adult MCD are presented in Box 1.
Several recommendations deserve discussion. Like in pediatric
NS, corticosteroids are recommended as first-line therapy (graded
1C). Clinicians will recognize that the dose of corticosteroids is
high enough to cause significant morbidity, such as Cushings syn-
drome, bone loss, and hyperglycemia, especially over the time sug-
gested (minimum 4weeks, maximum 16weeks, with a slow taper
up to 6months). Is it possible to achieve results with less? Direct
evidence from adults is largely lacking, but at least three recent
randomized controlled studies in children showed that extended
courses of steroids did not prevent the development of FR/SD
disease, just delayed its recognition (26–28). This prompted a revi-
sion to a Cochrane systemic review, concluding that the benefit of
prolonged courses of steroids was likely overestimated by earlier
studies and that it seems there is no benefit of increasing the dura-
tion of prednisone beyond 2–3months (6). Should these pediatric
studies influence practice in adults? Here, it is worth noting that
the KDIGO guidelines are based on low-quality evidence, and
indeed their “recommendation is based largely on extrapolation
from RCTs in children” (p. 177, emphasis ours).
A separate issue concerns the recommendations for alter-
native agents to corticosteroids. KDIGO suggests alternative
agents in patients with relative contraindications or intolerance
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BOX 1 KDIGO guidelines for minimal-change disease (MCD) in adults.
5.1: Treatment of initial episode of adult MCD
5.1.1: We recommend that corticosteroids be given for initial treatment of nephrotic syndrome. (1C)
5.1.2: We suggest prednisone or prednisolone be given at a daily single dose of 1mg/kg (maximum 80mg) or alternate-day single dose of 2mg/kg (maximum 120mg).
(2C)
5.1.3: We suggest the initial high dose of corticosteroids, if tolerated, be maintained for a minimum period of 4weeks if complete remission is achieved, and for a
maximum period of 16weeks if complete remission is not achieved. (2C)
5.1.4: In patients who remit, we suggest that corticosteroids be tapered slowly over a total period of up to 6months after achieving remission. (2D)
5.1.5: For patients with relative contraindications or intolerance to high-dose corticosteroids (e.g., uncontrolled diabetes, psychiatric conditions, severe osteoporosis),
we suggest oral cyclophosphamide or CNIs as discussed in frequently relapsing MCD. (2D)
5.1.6: We suggest using the same initial dose and duration of corticosteroids for infrequent relapses as in Recommendations 5.1.2, 5.1.3, and 5.1.4. (2D)
5.2: FR/SD MCD
5.2.1: We suggest oral cyclophosphamide 2–2.5mg/kg/day for 8weeks. (2C)
5.2.2: We suggest CNI (cyclosporine 3–5mg/kg/day or tacrolimus 0.05–0.1mg/kg/day in divided doses) for 1–2 years for FR/SD MCD patients who have relapsed
despite cyclophosphamide, or for people who wish to preserve their fertility. (2C)
5.2.3: We suggest MMF 500–1000mg twice daily for 1–2 years for patients who are intolerant of corticosteroids, cyclophosphamide, and CNIs. (2D)
5.3: Corticosteroid-resistant MCD
5.3.1: Re-evalulate patients who are corticosteroid resistant for other causes of nephrotic syndrome. (Not Graded)
5.4: Supportive therapy
5.4.1: We suggest that MCD patients who have AKI be treated with renal replacement therapy as indicated, but together with corticosteroids, as for a first episode of
MCD. (2D)
5.4.2: We suggest that, for the initial episode of nephrotic syndrome associated with MCD, statins not be used to treat hyperlipidemia, and ACE-I or ARBs not be used
in normotensive patients to lower proteinuria. (2D)
FR, frequently relapsing; SD, steroid dependent; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; AKI, acute kidney injury.
to high-dose corticosteroids (2D), or for patients with FR/SD
disease (2C/2D). Three agents are named: cyclophosphamide and
calcineurin inhibitors (CNIs) receive slightly stronger endorse-
ment, followed by mycophenolate mofetil (MMF). Several points
here deserve mention. One consideration is why these agents are
considered second-line behind steroids. There have been only
two controlled trials of steroids in adult MCD, only one placebo-
controlled (the other comparator was no treatment), involving,
respectively, 28 and 31 subjects (29). Steroids have never been
directly compared against alternate agents for initial treatment,
and observational data suggests similar (if not better) frequencies
of response to alternate agents (21, 22, 25). The strength of recom-
mendation supporting steroids rests largely on the totality of evi-
dence showing that steroids are effective (especially in children),
but NOT on evidence showing that other agents are ineffective
or that they are inferior to steroids. The reason steroids have
been studied more is that they have been used more, largely for
historical and circumstantial reasons (availability, affordability,
prescriber familiarity, etc.). There is certainly sufficient equipoise
to justify a randomized trial in adults comparing an alternative
(and one hopes better tolerated) agent to corticosteroids, though
only time will tell if the nephrology community deems this a
sufficient priority to pursue.
Recommendation 5.1.5 to use alternate agents for patients with
contraindications or intolerance to steroids is graded as 2D, a
suggestion based on low-quality evidence. It should be recog-
nized that the weakness of the evidence relates to the choice of
replacement, not to the premise of withholding steroids in the first
place – there need be very little “evidence” to justify NOT giving a
medicationwhich is poorly tolerated or contraindicated! In adults,
relative contraindications to steroid use are more common (e.g.,
diabetes, osteoporosis), as is steroid intolerance, and in clinical
decision-making individual patient considerations must trump
broad practice guidelines (30). Another nuance not specifically
considered in the guidelines, but reflected by the weak grading of
evidence, concerns the long-term sequelae of various therapeutic
choices. The justification for rating cyclophosphamide and CNIs
as nearly equivalent in the guidelines is based on observational
studies and a few small randomized trials comparing the two
[summarized in the guidelines and elsewhere (29)]. These stud-
ies have no information on potential long-term toxicities of the
drugs, for example, late malignancies from cyclophosphamide or
nephrotoxicity from CNIs. Obtaining such evidence is certainly
feasible; for instance, it was recently shown in a carefully followed
cohort of membranous nephropathy (another common cause of
idiopathic NS in adults) that treatment with cyclophosphamide
was associated with a more than threefold increased risk of subse-
quently developing cancer (31).
The anti-CD20 monoclonal antibody rituximab is not men-
tioned in the KDIGO guidelines on adult MCD, except in an
appeal for further research. In the years since the guidelines were
published, such research increasingly supports the efficacy of
rituximab in both children and adults, particularly for steroid
sensitive and SD/FR disease. The Rituximab for Childhood-onset
Refractory Nephrotic Syndrome Study in Japan was a multicenter,
double-blind, randomized trial of rituximab vs. placebo in 52
children with FR/SD NS (32). Median relapse-free survival was
267 days in the rituximab group compared to 101 days in the
placebo group (P< 0.0001). The rituximab group had signifi-
cantly fewer relapses, and required significantly less steroids. In
Italy, Ravani and colleagues carried out a multicenter, open-label,
randomized non-inferiority trial of rituximab vs. tapering steroid
therapy in 30 children with SD NS on high-dose prednisone (33).
The differences in relapse were dramatic; median time to relapse
was 18months for the rituximab group, whereas 14/15 children in
the control group relapsed within 4months. The rituximab group
received much lower cumulative doses of prednisone. Observa-
tional studies bolster the results of these randomized studies.
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Recent reports from large case series in children, and several
series of adults with MCD, have consistently found that rituximab
is associated with prolonged remissions and allows reduction
or cessation of steroids or other immunosuppressants in SD/FR
patients (34–38). In sum, these data support a role for rituximab
in the care of patients with SD/FR disease. Where rituximab
should rank among the various other immunosuppression choices
may be clarified by future head-to-head clinical trials and careful
cost-benefit analyses.
Adult Idiopathic FSGS
The KDIGO guidelines for adult FSGS are presented in Box 2.
Many of the treatment recommendations regarding steroid use
are analogous to those for MCD and recapitulate the issues dis-
cussed earlier. Some additional issues specific to FSGS are worth
exploring further.
The first two recommendations, 6.1.1 and 6.1.2, are not graded
and present a small paradox. The clinician is urged to perform
a thorough evaluation to exclude secondary forms of FSGS, but
what this evaluation should entail is left undefined except that it
should not include genetic testing. Following these non-graded
recommendations is a relatively strongly graded (1C) recommen-
dation that corticosteroids or immunosuppression be considered
only for “idiopathic FSGS with clinical features of nephrotic syn-
drome.” It is not specified which particular clinical features of NS
are sufficient to justify therapy.
The guidelines are necessarily vague because of the inher-
ent limitations in our classification of FSGS. It should be
clear that the purpose of these recommendations is to direct
steroids and immunosuppression to those patients with the
highest likelihood of response (idiopathic FSGS), while exclud-
ing those for whom such therapy is ineffective (most cases of
secondary FSGS). However, establishing a clear diagnosis of
idiopathic FSGS – and by extension, deciding whom to treat
with steroids/immunosuppression – is not trivial. There is no
evidence-based approach for ruling out secondary FSGS. The list
of conditions that may produce FSGS lesions on biopsy is long
and diverse (39). In the rationale, the KDIGO guidelines state,
“idiopathic FSGS is defined by exclusion of any other identifi-
able cause of secondary FSGS” (p. 181, emphasis ours), but this
definition is problematic. Obesity, diabetes, and hypertension all
may cause secondary FSGS, but these are common conditions and
none of them exclude the possibility of a separate or superimposed
“idiopathic” FSGS. Such issues present real, practical challenges
to the clinician attempting to apply the guidelines in deciding
whether to treat a patient with nephrotic-range proteinuria and
a biopsy showing FSGS lesions.
These concerns highlight the limitations of classifying FSGS as
“idiopathic” or “secondary.” At the heart of the matter is deter-
mining whether a patient’s cause of FSGS may be susceptible
to steroids or immunosuppression, given the overwhelming evi-
dence that achieving partial or complete remission with therapy
dramatically improves prognosis (40–44). Identifying the circulat-
ing factor or factors responsible for idiopathic FSGS remains a yet
unrealized hope, but one that when achieved should greatly assist
in determining which patients deserve a trial of immunotherapy
(as well as chipping away at the inelegant term, “idiopathic.”) In
the meantime, what evidence is available to help determine whom
to treat?
A potentially evolving role for genetic testing was discussed
previously, and in a future of personalized medicine may become
a routine part of the diagnostic workup. Some additional points
may be helpful. Deegens and colleagues showed that the degree
of foot process effacement, measured by electron microscopy,
was a sensitive and specific test to differentiate idiopathic from
secondary FSGS (45). In fact, foot process effacement seen in post-
reperfusion biopsies of transplanted kidneys diagnosed recurrent
FSGS with high specificity (46). By light microscopy, the perihilar
variant of FSGS is most characteristic of hyperfiltration injury, but
does not rule out idiopathic FSGS (47). Among clinical features,
normal serum albumin and lack of edema despite nephrotic-range
BOX 2 KDIGO guidelines for idiopathic focal segmental glomerulosclerosis (FSGS) in adults.
6.1: Initial evaluation of FSGS
6.1.1: Undertake thorough evaluation to exclude secondary forms of FSGS. (Not Graded)
6.1.2: Do not routinely perform genetic testing. (Not Graded)
6.2: Initial treatment of FSGS
6.2.1: We recommend that corticosteroid and immunosuppressive therapy be considered only in idiopathic FSGS associated with clinical features of the nephrotic
syndrome. (1C)
6.2.2: We suggest prednisone be given at a daily single dose of 1mg/kg (maximum 80mg) or alternate-day dose of 2mg/kg (maximum 120mg). (2C)
6.2.3: We suggest the initial high dose of corticosteroids be given for a minimum of 4weeks; continue high-dose corticosteroids up to a maximum of 16weeks, as
tolerated, or until complete remission has been achieved, whichever is earlier. (2D)
6.2.4: We suggest corticosteroids be tapered slowly over a period of 6months after achieving complete remission. (2D)
6.2.5: We suggest CNIs be considered as first-line therapy for patients with relative contraindications or intolerance to high-dose corticosteroids (e.g., uncontrolled
diabetes, psychiatric conditions, severe osteoporosis). (2D)
6.3: Treatment for relapse
6.3.1: We suggest that a relapse of nephrotic syndrome is treated as per the recommendations for relapsing MCD in adults (see Chapters 5.1 and 5.2). (2D)
6.4: Treatment for steroid-resistant FSGS
6.4.1: For steroid-resistant FSGS, we suggest that cyclosporine at 3–5mg/kg/day in divided doses be given for at least 4–6months. (2B)
6.4.2: If there is a partial or complete remission, we suggest continuing cyclosporine treatment for at least 12months, followed by a slow taper. (2D)
6.4.3: We suggest that patients with steroid-resistant FSGS, who do not tolerate cyclosporine, be treated with a combination of mycophenolate mofetil and high-dose
dexamethasone. (2C)
CNI, calcineurin inhibitors.
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FIGURE 1 | A suggested algorithm for the clinical approach to adult FSGS. *Note that KDIGO guidelines explicitly recommend against genetic testing.
**Highlighted are some of the monogenic causes of FSGS more likely to be found in adults with genetic disease; see text and highlighted references for further
discussion. NPHS2, Podocin; CD2AP, CD2-associated protein; ACTN4, α-actinin-4; INF2, inverted formin-2; TRPC6, transient receptor potential channel 6; WT1,
Wilms tumor protein.
proteinuria are common findings in secondary FSGS, but rare
in idiopathic FSGS (48). In the absence of nephrotic-range
proteinuria, immunosuppression is generally unnecessary since
subnephrotic patients have excellent long-term renal prognosis
with kidney survival rates exceeding 90% at 5–10 years on con-
servative therapy alone (43, 49, 50).
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The treatment of steroid-resistant FSGS remains particularly
challenging. KDIGO suggests cyclosporine with a 2B recommen-
dation. Tacrolimus, the other commonly used CNI, is not formally
recommended. The rationale cites the lack of randomized trials,
but also states that limited observational data suggests tacrolimus
may be an alternative to cyclosporine. Additional data published
after the KDIGO guidelines support this notion. A small, single-
center study of adults with idiopathic FSGS compared intravenous
monthly cyclophosphamide to tacrolimus for 6months, with both
groups receiving steroids (51). There were no significant differ-
ences between the groups, but both groups had improved pro-
teinuria and serum albumin with stable GFR. Tacrolimus was also
compared to cyclophosphamide in amulticenter randomized trial
of 131 childrenwith steroid-resistant NS (mostlyMCD and FSGS)
(52). Tacrolimus showed remarkably higher rates of complete or
partial remission (82.5 vs. 45.9%, P< 0.001), with shorter time to
remission and fewer serious infections. The superior likelihood of
remission was maintained in the subgroup with FSGS (HR 2.54,
95% CI 1.09–5.93, P= 0.03). In an uncontrolled trial of 44 adults
with steroid-resistant FSGS treated with tacrolimus for 24weeks,
52.3% of patients achieved complete or partial remission (53).
For steroid-resistant patients intolerant to cyclosporine,
KDIGO recommends only combined MMF and high-dose
dexamethasone. This is based on one large randomized trial
which reported that this combination had similar efficacy to
cyclosporine, but the limitations of this trial have been reviewed
in detail (54). No other agents receive formal recommendations;
in our view, this is largely appropriate for practice guidelines given
the limited evidence concerning other agents. Of note, no formal
recommendation is made for or against cytotoxics, although they
are explicitly discouraged in the KDIGO guidelines for steroid-
resistant NS in children (5). Rituximab has shown potential for
steroid-sensitive FSGS in case reports and small series, but it
appears largely ineffective for steroid-resistant disease (55–57).
A recent small series examined adrenocorticotropic hormone
gel in 24 patients with idiopathic FSGS and found that 7 (29%)
experienced remission with therapy, including 5/15 (33%) who
were steroid-resistant.
Figure 1 presents our suggested summary algorithm for the
diagnostic and therapeutic approach to an adult with FSGS on
kidney biopsy, which largely follows the KDIGO guidelines. Such
an algorithm, like the practice guidelines themselves, should not
supplant clinical judgment.
Conclusion
The KDIGO clinical practice guidelines have played a pioneering
role in providing evidence-based consensus recommendations for
treating glomerular diseases, including adult idiopathic NS.While
the recommendations are necessarily limited by the quality of
evidence underlying them, they serve an excellent starting point
for a discussion of the evidence-based approach to NS. New
research adds to, but rarely supplants, prior evidence, which is why
venerable “tried and true” interventions such as corticosteroids
continue to play such a prominent role in the recommendations.
As with all clinical practice guidelines, a critical appreciation of
their limitations and an eye toward emerging lines of evidence
are necessary to most effectively apply their lessons to individual
patients.
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